An analysis by researchers at the Brown University School of Public Health found that most studies exclude participants who ...

Challenges persist, as the clinical research sector can be slow to adopt these innovations. Comprehensive evidence and ...

ONS-5010 demonstrated to be non-inferior to Lucentis at 12 weeksBLA resubmission on track for calendar Q1 2025Entered into agreements for warrant inducement transaction expected to result in up to $20 ...

In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Ocugen (OCGN – Research Report), with a ...

Even so, broadening the range of trials’ participants can be practically useful, because they may lead to new medical ...

The current control strategy relies on regular deworming with albendazole and improvements in water, sanitation, and hygiene.

Tabelecleucel, an allogeneic, EBV-specific T-cell immunotherapy, works by targeting and eliminating EBV-infected cells.

The efficacy and safety of a proposed biosimilar and ustekinumab are similar among adults with moderate to severe plaque psoriasis.

Secukinumab delivers sustained efficacy and quality of life improvements in pediatric generalized pustular psoriasis (GPP).

H.C. Wainwright reaffirmed its Buy rating and $20.00 stock price target for Aprea Therapeutics (NASDAQ:APRE), a ...

iECURE's ECUR-506 showed promising safety and efficacy in a Phase ... Analyst Kostas Biliouris writes that early ECUR-506 efficacy provides initial clinical derisking of in vivo ARCUS efficacy ...